Skip to main content

An Integrated Platform for Developing Brain Cancer Diagnostic Techniques

Periodic Reporting for period 1 - AiPBAND (An Integrated Platform for Developing Brain Cancer Diagnostic Techniques)

Reporting period: 2018-01-01 to 2019-12-31

AiPBAND started on January 1, 2018 and will last 36 months until December 31, 2021. The project consortium consists of 13 beneficiaries (10 academic institutes, 3 SMEs) from 5 European countries and aims to train 14 ESRs in developing brain cancer diagnostic techniques.

Gliomas are the most common primary intracranial tumour, accounting for 81% of malignant brain tumours and although relatively rare, cause significant mortality and morbidity. About 45% of all gliomas are Glioblastoma (GBM) and is the most common histology with a 5-year relative survival of about 5%. Although adjuvant therapies, such as radiotherapy and chemotherapy are applicable and can prolong survival, GBM usually has a poor prognosis. Therefore, developing improved patient-oriented strategies for combating brain cancer is still one of the leading challenges faced by the EU. This ranges from prevention to more effective and earlier diagnosis, to better treatment with minimal side effects.

The long-term fight against brain cancer and lack of young interdisciplinary talents in the brain cancer diagnostic field requires intensive training of a new generation of early-stage researchers (ESR’s). AiPBAND aims to provide an excellent interdisciplinary, intersectoral and international (triple-i) research and training platform, with multidisciplinary expertise and cutting-edge technologies for developing innovative diagnostic techniques for brain cancer. Through this platform ESRs will be trained maximizing their potential of knowledge transformation, employability, and becoming future leaders in both academia and industry. AiPBAND brings together leading academic and industrial experts from four major consortia in Europe, their synergies enhance strongly the cross-sectoral participation and contribution to the research and training.
We have implemented the core management, research and training activities, developed communication and dissemination strategies, as well as creating a project website. 14 ESRs have been recruited and enrolled on PhD programmes and all appropriate ethics processes are in place.

AiPBAND research activities are grouped into five work packages (WPs)

WP1- The protocols of three biosensors have been developed, which can be used to test different types of biomarkers in the blood, including a graphene-based biosensor for the detection and quantification of methylated tumour suppressor gene (MGMT). Results of this work were successfully accepted for presentation at the 30th Anniversary World Congress on Biosensors. An optical biosensor platform using Surface Plasmon Resonance Imaging (SPRi) technology has been developed to detect GBM-associated miRNA biomarker. A review paper has been published about the applicability of SPR and localized SPR (LSPR)-based platforms (Bellassai N. et.al. Front Chem. 2019). Further optimization of the assay is required to provide a better enhancement factor. Moreover, digital ELISA bioassay for detecting multiplex protein and nucleic acid biomarkers at extremely low concentrations has been established. The platform shows a great degree of flexibility, offering a possibility for implementing multiplex assays to detect more than one target per sample.

WP2- Initial biomarker panels for GBM has been produced by a comprehensive literature review study which includes microRNA and protein biomarkers in body fluids and a survival prediction model for GBM was developed. In addition, a panel of miRNA biomarkers has been identified by next generation sequencing techniques. The plasma proteogenomics method has been developed and a GBM stem-cell panel has been profiled, using RNAseq and in-depth MS to detect stem cell specific proteins. The plasma and tissue validation cohort is currently being collected. Two relevant papers have been published (Pernemalm M., et. al., eLife, Issue 8, 2019; Chandran V.I. Clinical Cancer Research, 2019). Moreover, an in silico data-mining study to identify DNA methylation biomarkers is being carried out.

WP3- A machine learning model to integrate DNA methylation and gene expression data for cancer discrimination has been developed and published (Zhang X., Proceedings 2019 IEEE International Conference on Bioinformatics and Biomedicine). In addition, a query database has been developed to explore potential known biomarkers in brain cancer. Also, the architecture for an innovative cloud-based brain tumour diagnostic platform (CBDP) has been proposed for further development.

WP4- The protocol of developing a pre-clinical mouse model that accurately recreates the molecular profile reported in GBM patients has been developed. The model will be established to validate blood biomarkers identified in AiPBAND. Genetically characterised brain tumour samples from patients with glioblastoma and other forms of high-grade glioma have been provided too. These samples are made available for RNA sequencing and spatial transcriptome. In addition, a novel clinical trial strategy has been designed to reduce bias and false positive in biomarkers research. The validations of miRNA and protein biomarkers using two biosensors respectively are ongoing.

WP5- The current business model of an AiPBAND SME has been intensely investigated and a working draft of the AiPBAND Business Model (BM) canvas to reflex the possible BMs proposed. Further work will follow to develop and explore the innovative diagnostics and business models for potential industrial exploitations and clinical applications across Europe.

In parallel with the research developed by ESRs, a tailored training programme was implemented, covering fundamental and transferable skills. During this report period, six network-wide training events have been organised, which ESRs have been engaged in, from online presence to in person activitie
AiPBAND is a multi-disciplinary project with research fields involving neuroscience, biotechnology, big data computing, etc. Our approach provides the foundation for a comprehensive research strategy and enhances strongly the cross-sectoral participation and contribution to the research and training programme. New biosensor technologies, biomarkers, diagnostic models and warehousing, clinical validation strategy, as well as business model developed in AiPBAND may also have significant impact within the broader disease diagnosis.

Using blood biomarkers for disease diagnosis as a non-invasive and low costing approach has the potential to detect GBM at its early stage. Comparing to single type blood biomarkers for complex disease detection, novel multi-type biomarker and biosensor approach empowered by advanced machine learning strategy provide an enhanced mutual complementary solution and has the advantage of detecting brain cancer earlier with higher accuracy and lower concentration. The benefit of AiPBAND will ultimately be experienced by researchers, patients with cancer, clinical doctors and healthcare systems across Europe and beyond.

The goal of this project is being addressed by implementing innovative individual research projects which are used as a research platform for training ESRs in the latest methodologies and technologies in the early diagnosis of human disease. The training programme is further strengthened by comprehensive triple-i secondment and network-wide training to maximize their knowledge transformation and employability and become future leaders in both academia and industry.
AiPBAND Network Event in Catania, Italy, 2019
AiPBAND Network Event in Rome, Italy, 2018